Product Pipeline
Rapid discovery of disease targets and drug candidates has been Corixa's strength since the company was founded in 1994. Validated discovery -- the rigorous scientific and operational evaluation of compounds at all stages of development -- greatly improves our key programs' commercialization potential. We evaluate prospects according to their performance in vitro, clinical viability, partnership potential and patient demand, among many other factors. We only allocate development resources to candidates that stand up to this level of scrutiny and continuously prioritize programs early in the process. We are committed to preparing and consistently submitting Investigational New Drug Applications each year, either in collaboration with our partners or on our own. As the number of validated candidates entering the clinic increases, so do our chances for long-term success.
Whether we've identified a potential treatment for breast cancer, hepatitis or allergy, we view each candidate through the focuses lens of our validated development program defining a clear path from concept to commercialization.
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's products and adjuvants for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, SEC filings, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.